The National Institute of Health and Clinical Excellence has published new guidance for the month of May.
The coeliac disease guideline (QRG) covers the recognition and assessment of coeliac disease and the care of children and adults who are undergoing the diagnostic process for coeliac disease.
The low back pain guideline (QRG) specifically addresses the care and treatment that people who have persistent non-specific low back pain.
The type 2 diabetes guideline (QRG) provides an update to previous guidelines by clarifying the place in therapy for gliptins (sitagliptin and vildagliptin), glitazones (pioglitazone and rosiglitazone) and exenatide. These treatments are recommended in cases where there is intolerance to established agents (metformin or sulphonylureas) or in combination with the established agents when initiation of insulin is unacceptable for employment, social or other reasons.
Action: Clinicians who see and treat any of the above conditions will find these guidelines useful and informative.
|« MeReC Extra 39||Aspirin for primary prevention? »|